Co-Diagnostics (NASDAQ:CODX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Co-Diagnostics (NASDAQ:CODX) posted its earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02), Zacks reports. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%. The firm had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.38 million.

Co-Diagnostics Trading Down 6.4 %

Shares of CODX opened at $0.39 on Friday. The stock has a 50 day moving average of $0.62 and a 200 day moving average of $0.90. The company has a market capitalization of $12.45 million, a price-to-earnings ratio of -0.28 and a beta of 1.29. Co-Diagnostics has a 12 month low of $0.33 and a 12 month high of $2.23.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.